Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharma-Reporter" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharma-Reporter for you to read. Along with our medical data and news we also list BioPharma-Reporter Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharma-Reporter Companies for you to search.
Lonza announced it would invest in two new âIbex Solutionsâ, which offer manufacturing capabilities to biotechs developing antibody therapies.
TriLink BioTechnologies, a subsidiary of Maravai, that provides gene therapy services to researchers, has announced it will relocate to expand the companyâs operations.
NICE has deemed Novartisâ CAR T-cell therapy Kymriah too expensive for the UK market.
As the stream of executives flowing from large pharma companies to smaller biotechs builds into a torrent, another month has passed with a number of significant switches. Notably, two former Genentech employees, responsible for work on some of its bestselling products, have made the move to become executives at a very early stage biotech that has only just completed a Series B financing.
Mitra Biotech and Glenmark Pharmaceuticals have partnered to advance research on Glenmarkâs immuno-oncology treatments using Mitraâs platform.
A study demonstrated that IV immunogloubin may be able to help treat a subset of individuals with autism spectrum disorder.
Novo Nordisk will restructure its R&D operations through the increased investment made possible by laying off 400 members of staff.
Regulatory setbacks at Tevaâs CMO facility in Korea have not halted the regulatory progression of preventive migraine treatment Ajovy, which has received US FDA approval.
Scientists demonstrated that an adjuvant to an immunotherapy vaccine resulted in a 100% survival rate in mice with aggressive melanoma.
Boehringer Ingelheim will pay â210m for ViraTherapeutics to boost viral-based immune-oncology R&D.
BioPharma-Reporter (BPR) discusses with Jennifer Fox (JF), co-chair of Brinks Gilson & Lioneâs biopharma practice group, the provisional detail revealed from the US administrationâs proposed trade deal with Mexico, and its potential impact on the biopharma industry.
According to DelSiTech, biodegradable parenteral drug delivery technology could help create a âpatient-friendly approachâ to biologics delivery.
Thermo Fisher Scientific announced the acquisition of BDâs Advanced Bioprocessing unit, which will join its Life Sciences Solution business.
As Nordic Life Science Days draws to a close for 2018, so too do the conference âsuper sessionsâ, covering patient engagement, precision medicine, drug delivery and immune-oncology. Biopharma-Reporter is on the ground, bringing you the social media buzz direct from Scandinavia.
3M used the platform of Biotech Week Boston to discuss its updated Emphaze AEX Hybrid Purifier product.
Morphogenesis launched its first in-human melanoma clinical study with Moffitt Cancer Center, as part of Moffittâs Cutaneous Oncology Program.
A fortuitous finding in preclinical research, whereby mice injected with a modified protein developed hair, has prompted Follicum ABâs research and development into the alopecia space.
GlaxoSmithKline received a rejection for the use of its Nucala product in patients with COPD.
MilliporeSigma used Biotech Week Boston to discuss the release of its Eshmuno CP-FT resin and how it can improve downstream efficiency.
Seqirus received approval on its cell-based flu vaccine manufacturing process from the FDA, not long after its FY18 earnings showed profitability.
A researcher at UVA medical school has developed a âtwo-headedâ antibody approach to treat ovarian cancer and solid tumors.
A research team at VIB-UGent developed an immunotherapy treatment that destroyed tumors while stimulating the immune system in mice which may improve efficacy of checkpoint inhibitors.
The NHS has signed a commercial deal with Novartis, which will see âgame changerâ therapy Kymriah supplied to children and young people in the UK.
BioProcess International has kicked off at Biotech Week Boston. BioPharma-Reporter is here to cover the best of the sessions and the reactions from everyone present.
The CDNA has accepted Bio-Thera Solutions BLA for a biosimilar to Humira for review.